Prevention and treatment of cancer-related infections, version 2.2016

Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel ShohamRandy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann, Courtney Smith

Research output: Contribution to journalReview articlepeer-review

143 Scopus citations

Abstract

Infectious diseases are important causes of morbidity and mortality in patients with cancer. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prevention and Treatment of Cancer-Related Infections characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This portion of the guidelines highlights the sections on antifungal and antiviral prophylaxis. Antifungal and antiviral prophylaxis recommendations have expanded over the past few years. New agents for the treatment of fungal infections and incorporation of therapeutic drug monitoring are presented. Antiviral prophylaxis for hepatitis B and management considerations for hepatitis C and HIV have been further developed.

Original languageEnglish (US)
Pages (from-to)882-913
Number of pages32
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number7
DOIs
StatePublished - Jul 1 2016

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Prevention and treatment of cancer-related infections, version 2.2016'. Together they form a unique fingerprint.

Cite this